A total of 15 out of 132 (11.4%) patients with LUAD and 17 of 177 (9.6%) with NSCLC were assessed as being BHLHE41 positive (Table 2 and Table S1). This evidence concerns the gene BHLHE41 and non-small cell lung carcinoma.